

Gemini Adds Bob Stefanowski as Director

** Bob Stefanowski, former Director of Quintiles and executive at General Electric, 3i Group and UBS, named Director of Gemini Bio-Products*

West Sacramento, CA, April 3, 2019 – Gemini Bio-Products (“Gemini”), a BelHealth Investment Partners portfolio company based in West Sacramento, California, today announced that Bob Stefanowski has joined its Board of Directors. Gemini is a leading biological reagents manufacturer and supplier serving the scientific community across academic research and the biotechnology and biopharma industries.

Mr. Stefanowski has successfully led major corporations. His prior positions include: CEO and President of several divisions of General Electric (NYSE: GE), including Commercial & Industrial Finance and Telecom, Media & Technology Finance; Chief Financial Officer of UBS Investment Bank (NYSE: UBS); Chairman and Managing Partner of 3i Group, a middle-market Private Equity investment firm; and CEO of DFC Global.

Mr. Stefanowski was the winner of the Republican Primary for Governor of the State of Connecticut over four other challengers, becoming the Republican Candidate for Governor, narrowly losing to Democratic Governor Ned Lamont in November 2018.

From 2008 to 2011, Mr. Stefanowski was a Director of Quintiles, the world’s largest provider of life sciences product development and integrated healthcare services and predecessor to IQVIA (NYSE: IQV). Under management’s leadership, the business completed nine acquisitions, nearly doubling its revenue from \$2.8bn to \$4.5bn, and growing EBITDA over 250% before listing publicly in 2013. Quintiles expanded its commercial services into the Middle East, North Africa and East Africa, and developed numerous clinical development and joint venture partnerships.

Harold S. Blue, Managing Partner of BelHealth stated, “We are delighted to welcome Bob to the Board of Gemini. Bob has an impressive 30-year background in key financial positions and relevant life science experience on the board of Quintiles. His insights will be extremely valuable to Gemini at a time when we are focused on extending our position as a high-quality supplier to the cell and gene therapy markets.”

About Gemini Bio-Products

Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top biotechnology firms, research and academic communities, and pharmaceutical companies. Today, Gemini operates from a manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serve cell culture laboratories worldwide.

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current \$350 million fund.

For further information, please visit:

BelHealth Investment Partners: www.belhealth.com

Contact:

BelHealth Investment Partners: Inder Tallur (347) 308-7018

Gemini Bio-Products: Dale Gordon (916) 273-5228